LB-102 Significantly Improves Disease Severity in Acute Schizophrenia, with John Kane, MD
LB-102: A New Horizon in Schizophrenia Treatment LB Pharmaceuticals has recently unveiled promising data from the NOVA phase 2 study at the 2025 Annual Congress of the Schizophrenia International Research Society. The study evaluated LB-102, a new benzamide antipsychotic, showing significant improvements in disease severity for patients with acute schizophrenia. With mean changes in Clinical … Read more